Via EDGAR
|
|
|
|
U.S. Securities and Exchange Commission |
|
|
Division of Corporation Finance |
|
|
100 F Street, N.E. |
|
|
Washington, D.C. 20549-3720 |
|
|
Attention: |
Amanda Ravitz |
|
|
Timothy Buchmiller |
|
|
|
|
|
|
Re: |
Pulse Biosciences, Inc. |
|
|
|
Registration Statement on Form S-3 |
|
|
|
Filed October 25, 2018 |
|
|
|
File No. 333-227974 |
Acceleration Request
|
|
|
|
|
|
Requested Date: |
November 6, 2018 |
|
|
Requested Time: |
4:00 PM Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-227974) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf.
The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, at (650) 849-3240.
Please direct any questions or comments regarding this acceleration request to Andrew D. Hoffman at (650) 849-3240.
*****
Securities and Exchange Commission
Re: Pulse Biosciences, Inc.
November 2, 2018
Page 2
|
|
Sincerely, |
|
|
|
|
|
|
|
PULSE BIOSCIENCES, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Brian B. Dow |
|
|
|
Brian B. Dow |
|
|
|
Senior Vice President and Chief Financial Officer |
|
|
cc: |
Andrew D. Hoffman, Esq. |
|
|
|
Wilson Sonsini Goodrich & Rosati, Professional Corporation |